MOUSE CORE
MOUSE CORE
批准号:
8744944
负责人:
MICHAEL I. NISHIMURA
金额:
$20.49万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-09-04 至 2016-08-31
关键词:
AccountingAddressAdoptive ImmunotherapyAffinityAntigensAutologousBeliefBiologicalBreedingCD4 Positive T LymphocytesCell TherapyCellsClinical TrialsCore FacilityDevelopmentFailureGene-ModifiedGenerationsGoalsHLA-A2 AntigenHumanImmuneImmune responseImmunityImmunologic ReceptorsImmunotherapeutic agentImmunotherapyIndividualInfusion proceduresInstructionInterferonsLinkMAPK9 geneMaintenanceMelanoma CellMetastatic MelanomaModalityModelingMonophenol MonooxygenaseMouse StrainsMusNormal tissue morphologyOutcomePatientsPeptidesPopulationProgram Research Project GrantsProteinsQuality ControlRegulatory T-LymphocyteResearchResearch PersonnelSeminalSourceSurfaceT cell responseT-Cell ReceptorT-Cell Receptor GenesT-LymphocyteTherapeuticTherapeutic InterventionTransgenic MiceTransgenic OrganismsTranslatingTumor AntigensTumor-Infiltrating LymphocytesVaccinationVirus DiseasesWorkcancer therapycellular engineeringclinically relevantcostgene therapygranzyme Bimprovedmedical specialtiesmelanomamelanoma-associated antigenmouse modelnoveloperationprogramsreceptorresearch studyresponsetumortumor growth
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY (See instructions);
Seminal work on the identity of human melanoma associated antigen have led to the development of novel adoptive immunotherapeutic strategies in cancer treatment that involves isolation of antigen-specific cells, their ex vivo expansion and activation, and subsequent autologous administration for inducing anti-tumor immune responses. In an effort to make adoptive immunotherapy more broadly available, strategies to genetically transfer tumor specific immune receptors into patient's autologous T cells via T cell receptor (TCR) gene therapy are being pursued intensely. Successful outcome for adoptive T cell immunotherapy has been linked to persistence of the effector T cell population. However several biological mechanisms may still account for the failure to achieve efficient immune protection. To address various constraints that may arise when using the high affinity TCR for adoptive immunotherapy, we recently developed transgenic mouse model expressing TIL1383I TCR, same human HLA-A2 restricted high affinity TCR reactive to human tyrosinase-derived peptide YMDGTMSQV isolated from a class-l restricted CD4* T cells of tumor infiltrating lymphocytes (TILs) of a patient with metastatic melanoma, that is being used in clinical trials. The transgenic mouse expressing the TIL1383I TCR presents a clinically relevant model, which provides us with a unique opportunity to compare TCR transduced T cells with a normal unmanlpulated population of T cells bearing the same receptor. Therefore, the TIL1383I TCR bearing transgenic mouse (referred as h3T - human TIL derived Tyrosinase TCR) model will be extensively used as a key source of cells for comparisons in experiments proposed by projects 1-4. The mouse core will provide quality-controlled donor mouse cells to projects 1-4 and Core C. In addition the core will maintain breeding colonies of recipient mice, generate additional hST specialty strains, and maintain other specialty strains as needed for individual projects. The centralized operation of mouse maintenance will have the advantages of reduced cost, consistency among projects due to centralized quality control, and ease of use for the investigators. Thus, the aims of this mouse core facility are 1) To provide quality-controlled donor mouse T cells from TIL 13831 TCR bearing h3T transgenic mice, 2) To maintain breeding colonies of mice, which are used as recipient strains, and 3) To develop novel strains of TIL 13831 TCR transgenic mice and maintain breeding colonies of mice that will be specifically utilized by individual Projects in the Program.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ADMINISTRATIVE CORE
-
批准号:8744937
-
项目类别:
-
资助金额:$9.66万
-
财政年份:2013
-
负责人:MICHAEL I. NISHIMURA
-
依托单位:
IMPACT OF AICD ON TCR TRANSDUCED T CELLS FOR ADOPTIVE IMMUNOTHERAPY
-
批准号:8744932
-
项目类别:
-
资助金额:$29.72万
-
财政年份:2013
-
负责人:MICHAEL I. NISHIMURA
-
依托单位:
CELL THERAPY CORE
-
批准号:8744942
-
项目类别:
-
资助金额:$101.08万
-
财政年份:2013
-
负责人:MICHAEL I. NISHIMURA
-
依托单位:
IMPACT OF IMMUNE SUPPRESSION ON TCR-TRANSDUCED T CELLS FOR ADOPTIVE
-
批准号:8744934
-
项目类别:
-
资助金额:$20.53万
-
财政年份:2013
-
负责人:MICHAEL I. NISHIMURA
-
依托单位:
TCR TRANSDUCED CDB T CELLS FOR ADOPTIVE IMMUNOTHERAPY
-
批准号:8744928
-
项目类别:
-
资助金额:$28.57万
-
财政年份:2013
-
负责人:MICHAEL I. NISHIMURA
-
依托单位:
CLINICAL TRIALS USING TCR TRANSDUCED T CELL FOR ADOPTIVE IMMUNOTHERAPY
-
批准号:8744936
-
项目类别:
-
资助金额:$73.5万
-
财政年份:2013
-
负责人:MICHAEL I. NISHIMURA
-
依托单位:
BIOSTATISTICS CORE
-
批准号:8744938
-
项目类别:
-
资助金额:$12.5万
-
财政年份:2013
-
负责人:MICHAEL I. NISHIMURA
-
依托单位:
TCR TRANSDUCED CD4 T CELLS FOR ADOPTIVE IMMUNOTHERAPY
-
批准号:8744931
-
项目类别:
-
资助金额:$18.12万
-
财政年份:2013
-
负责人:MICHAEL I. NISHIMURA
-
依托单位:
Cell Therapy Core
-
批准号:8555364
-
项目类别:
-
资助金额:$104.13万
-
财政年份:2011
-
负责人:MICHAEL I. NISHIMURA
-
依托单位:
TCR Transduced CD4+ T Cells for Adoptive Immunotherapy
-
批准号:8555358
-
项目类别:
-
资助金额:$26.95万
-
财政年份:2011
-
负责人:MICHAEL I. NISHIMURA
-
依托单位:
TCR Gene Modified T Cells for Adoptive Immunotherapy
-
批准号:8175611
-
项目类别:
-
资助金额:$203.26万
-
财政年份:2011
-
负责人:MICHAEL I. NISHIMURA
-
依托单位:
Administrative Core
-
批准号:8555362
-
项目类别:
-
资助金额:$18.95万
-
财政年份:2011
-
负责人:MICHAEL I. NISHIMURA
-
依托单位:
TCR Gene Modified T Cells for Adoptive Immunotherapy
-
批准号:8730097
-
项目类别:
-
资助金额:$329.57万
-
财政年份:2011
-
负责人:MICHAEL I. NISHIMURA
-
依托单位:
TCR Gene Modified T Cells for Adoptive Immunotherapy
-
批准号:8336841
-
项目类别:
-
资助金额:$349.3万
-
财政年份:2011
-
负责人:MICHAEL I. NISHIMURA
-
依托单位:
TCR Gene Modified T Cells for Adoptive Immunotherapy
-
批准号:8550001
-
项目类别:
-
资助金额:$314.16万
-
财政年份:2011
-
负责人:MICHAEL I. NISHIMURA
-
依托单位:
TCR Engineering of Quiescent Primary Human T Cells
-
批准号:8004586
-
项目类别:
-
资助金额:$19.25万
-
财政年份:2010
-
负责人:MICHAEL I. NISHIMURA
-
依托单位:
TCR Engineering of Quiescent Primary Human T Cells
-
批准号:8079604
-
项目类别:
-
资助金额:$2.89万
-
财政年份:2010
-
负责人:MICHAEL I. NISHIMURA
-
依托单位:
TCR Engineering of Quiescent Primary Human T Cells
-
批准号:8426752
-
项目类别:
-
资助金额:$12.67万
-
财政年份:2010
-
负责人:MICHAEL I. NISHIMURA
-
依托单位:
TCR Affinity and Therapeutic Efficacy of T Cells
-
批准号:7909490
-
项目类别:
-
资助金额:$29.97万
-
财政年份:2009
-
负责人:MICHAEL I. NISHIMURA
-
依托单位:
TCR Affinity and Therapeutic Efficacy of T Cells
-
批准号:7939349
-
项目类别:
-
资助金额:$12.29万
-
财政年份:2009
-
负责人:MICHAEL I. NISHIMURA
-
依托单位:
海外基金